Incremental, Not Monumental, Win for Empagliflozin in HFpEF Incremental, Not Monumental, Win for Empagliflozin in HFpEF
The modest effects compel clinicians to be selective in the use of this costly drug, but there will be subgroups of patients who may benefit more, says John Mandrola, MD.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2021 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news
EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection fraction, a practice-changing result.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 27, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
emperor-preserved-heart-failure-full-data
Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction In this clinical first for adults with heart failure with preserved ejection fraction, empagliflozin demonstrated an impressive 21 percent relative risk reduction in the composite primary endpoint of cardiovascular death or hospitalization for heart failure1The benefit in the primary endpoint was independent of ejection fraction or diabetes status1Empagliflozin also reduced the relative risk of first and recurrent hospitalizations for heart fai...
Source: Boehringer Ingelheim Corporate News - August 27, 2021 Category: Research Source Type: news
FDA Okays Empagliflozin for HFrEF FDA Okays Empagliflozin for HFrEF
The drug is approved as a treatment for adults with heart failure with reduced ejection fraction (HFrEF) regardless of whether patients have diabetes.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 19, 2021 Category: Cardiology Tags: Cardiology News Alert Source Type: news
FDA Approves Jardiance (empagliflozin) to Treat Adults Living with Heart Failure with Reduced Ejection Fraction
Ridgefield, Conn. and Indianapolis, August 18, 2021– Jardiance (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 18, 2021 Category: Drugs & Pharmacology Source Type: news
EMPEROR-Preserved: Positive Top-Line Results for Empagliflozin in HFpEF EMPEROR-Preserved: Positive Top-Line Results for Empagliflozin in HFpEF
The SGLT2 inhibitor met the primary endpoint in adults with heart failure and preserved ejection fraction, with full results to be presented at ESC 2021.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news
emperor-preserved-heart-failure-toplineresults
Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction with empagliflozin for the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction (HFpEF)HFpEF has been classified as “the single largest unmet need in cardiovascular medicine”1 based on prevalence, poor outcomes and the absence of clinically proven therapies to date2With approval, em...
Source: Boehringer Ingelheim Corporate News - July 6, 2021 Category: Research Source Type: news
Synjardy XR (empagliflozin and metformin extended-release)
Title: Synjardy XR (empagliflozin and metformin extended-release)Category: MedicationsCreated: 7/2/2021 12:00:00 AMLast Editorial Review: 7/2/2021 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - July 2, 2021 Category: Endocrinology Source Type: news
Synjardy (empagliflozin and metformin)
Title: Synjardy (empagliflozin and metformin)Category: MedicationsCreated: 6/30/2021 12:00:00 AMLast Editorial Review: 6/30/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 30, 2021 Category: Drugs & Pharmacology Source Type: news
Glyxambi (empagliflozin and linagliptin)
Title: Glyxambi (empagliflozin and linagliptin)Category: MedicationsCreated: 6/29/2021 12:00:00 AMLast Editorial Review: 6/29/2021 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - June 29, 2021 Category: Endocrinology Source Type: news
real-world-benefit-shown-in-T2D-treatment
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kidney injury requiring dialysis, compared to DPP-4 inhibitorsThis analysis, which includes European data pooled with data from Israel and East Asia, was presented for the first time at the American Diabetes Association Scientific Sessions, 25 June 20211 EMPRISE data complement the la...
Source: Boehringer Ingelheim Corporate News - June 28, 2021 Category: Research Source Type: news
reduced-heart-failure-treatment-approval-europe
Jardiance ® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fractionThis new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization for heart failure with reduced ejection fraction in adults with or without diabetes and an eGFR of ≥20ml/min/1.73 m2Heart failure is the leading cause of hospitalization in Europe, with prevalence expected to increase as the population agesJardiance was first approved in May 2014 for the treatment of adults with ins...
Source: Boehringer Ingelheim Corporate News - June 21, 2021 Category: Research Source Type: news
Pill for diabetics could also protect against heart failure
The medication, empagliflozin, is thought to stimulate the heart, making it more efficient and leading to 'significant improvements' in function after just three months. (Source: the Mail online | Health)
Source: the Mail online | Health - June 12, 2021 Category: Consumer Health News Source Type: news
emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for Jardiance ® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fractionThe positive opinion is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk of cardiovascular death or hospitalization for heart failure The results were observed in adults with heart failure with reduced ejection fraction (HFrEF), with or without diabetesJardiance is currently indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 21, 2021 Category: Research Source Type: news
Empagliflozin least costly option for preventing heart failure in T2DM patients?
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news
